Patents by Inventor Jerôme Emile Georges Guillemont

Jerôme Emile Georges Guillemont has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11597704
    Abstract: This application relates to quinazoline derivatives of formula (I), pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds of formula (I) in the treatment or prevention of a viral infection, of a virus-induced disease, of cancer or of an allergy.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: March 7, 2023
    Assignee: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
    Inventors: David Craig Mc Gowan, Werner Constant Johan Embrechts, Jérôme Émile Georges Guillemont, Ludwig Paul Cooymans, Tim Hugo Maria Jonckers, Pierre Jean-Marie Raboisson
  • Publication number: 20230014173
    Abstract: The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
    Type: Application
    Filed: September 17, 2021
    Publication date: January 19, 2023
    Applicant: Janssen Sciences Ireland UC
    Inventors: Jérôme Émile Georges Guillemont, Magali Madeleine Simone Motte, Pierre Jean-Marie Bernard Rabiosson, Abdellah Tahri
  • Publication number: 20220389008
    Abstract: The present invention relates to the following compounds pounds (I) wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis (e.g. in combination).
    Type: Application
    Filed: September 29, 2020
    Publication date: December 8, 2022
    Inventors: Jérôme Émile Georges GUILLEMONT, Magali Madeleine Simone MOTTE, Steffen Friedrich Walter WEIDNER, Ellen Anita LANCKACKER, Godelieve Maria J. LAMMENS, Dirk Antonie LAMPRECHT
  • Publication number: 20220372033
    Abstract: The present invention relates to the following compounds (I) wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis (e.g. in combination).
    Type: Application
    Filed: September 29, 2020
    Publication date: November 24, 2022
    Inventors: Jérôme Émile Georges GUILLEMONT, Steffen Friedrich Walter WEIDNER, Ellen Anita LANCKACKER, Godelieve Maria J. LAMMENS, Dirk Antonie LAMPRECHT
  • Patent number: 11491157
    Abstract: The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection. (Formula I).
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: November 8, 2022
    Assignee: Janssen Sciences Ireland Unlimited Company Co Cork, IE
    Inventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Peter Rigaux, Antoine Benjamin Michaut
  • Publication number: 20220340564
    Abstract: The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
    Type: Application
    Filed: September 11, 2020
    Publication date: October 27, 2022
    Inventors: Jérôme Émile Georges GUILLEMONT, Magali Madeleine Simone MOTTE, Maria Cristina VILLELLAS ARILLA, Godelieve Maria J LAMMENS, Adeline Julie Dominique Marie RENÉ, Matthieu Ludovic JEANTY, Dirk Antonie LAMPRECHT
  • Patent number: 11339165
    Abstract: The invention concerns compounds having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection. Formula (Ia).
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: May 24, 2022
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Peter Rigaux, Antoine Benjamin Michaut, Guillaume Jean Maurice Mercey
  • Publication number: 20220033396
    Abstract: The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial vims (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment or prevention of respiratory syncytial vims infection.
    Type: Application
    Filed: November 25, 2019
    Publication date: February 3, 2022
    Inventors: Jérome Émile Georges GUILLEMONT, David Francis Alain LANÇOIS, Sovy CHAO, Patrick René ANGIBAUD, Guillaume Jean Maurice MERCEY, Pierre Jean-Marie Bernard RABOISSON, Antoine Benjamin MICHAUT, Peter RIGAUX
  • Publication number: 20210387997
    Abstract: This invention relates to dihydropyranopyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.
    Type: Application
    Filed: June 23, 2021
    Publication date: December 16, 2021
    Inventors: Tim Hugo Maria JONCKERS, Pierre Jean-Marie Bernard RABOISSON, Jérôme Émile Georges GUILLEMONT, David Craig MC GOWAN, Werner Constant Johan EMBRECHTS, Ludwig Paul COOYMANS, Laurent CALMUS
  • Patent number: 11180472
    Abstract: The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: November 23, 2021
    Assignee: Janssen Sciences Ireland UC
    Inventors: Jérôme Émile Georges Guillemont, Magali Madeleine Simone Motte, Pierre Jean-Marie Bernard Rabiosson, Abdellah Tahri
  • Patent number: 11179396
    Abstract: The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: November 23, 2021
    Assignee: Janssen Sciences Ireland UC
    Inventors: Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Abdellah Tahri
  • Patent number: 11117887
    Abstract: The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: September 14, 2021
    Assignee: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
    Inventors: Tim Hugo Maria Jonckers, David Craig McGowan, Jérôme Émile Georges Guillemont, Werner Constant J Embrechts, Guillaume Jean Maurice Mercey, Christophe Francis Robert Nestor Buyck, Wendy Mia Albert Balemans, Pierre Jean-Marie Bernard Raboisson
  • Patent number: 11084826
    Abstract: The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: August 10, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Boris Rogovoy, Vadim Bichko, Delphine Yvonne Raymonde Lardeau, Antoine Benjamin Michaut, Anil Koul
  • Publication number: 20210214317
    Abstract: This invention relates to pyrimidine prodrug derivatives, processes for their preparation, pharmaceutical compositions, and their use in therapy.
    Type: Application
    Filed: March 25, 2021
    Publication date: July 15, 2021
    Inventors: Jérôme Émile Georges GUILLEMONT, Tim Hugo Maria JONCKERS, Pierre Jean-Marie Bernard RABOISSON, David Craig MC GOWAN, Werner Constant Johan EMBRECHTS, Bart Henri Theresia STOOPS, Florence Marie HERSCHKE, Jacques Armand Henri BOLLEKENS, Laurent Jacques Emile CALMUS
  • Patent number: 11053256
    Abstract: This invention relates to dihydropyranopynmidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: July 6, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Jérôme Émile Georges Guillemont, David Craig McGowan, Werner Constant Johan Embrechts, Ludwig Paul Cooymans, Laurent Calmus
  • Patent number: 10981891
    Abstract: The present invention relates to compounds of formula (I) including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of tuberculosis.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: April 20, 2021
    Assignees: The Global Alliance for TB Drug Development, Inc., Janssen Pharmaceutica NV
    Inventors: Anna Marie Upton, Christopher Blair Cooper, Koenraad Jozef Lodewijk Marcel Andries, Jerome Emile Georges Guillemont, Walter Marcel Mathilde Van den Broeck, Brian Desmond Palmer, Zhenkun Ma
  • Patent number: 10968184
    Abstract: This invention relates to pyrimidine prodrug derivatives, processes for their preparation, pharmaceutical compositions, and their use in therapy.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: April 6, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Jérôme Émile Georges Guillemont, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, David Craig McGowan, Werner Constant Johan Embrechts, Bart Henri Theresia Stoops, Florence Marie Herschke, Jacques Armand Henri Bollekens, Laurent Jacques Emile Calmus
  • Publication number: 20210094958
    Abstract: The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Application
    Filed: April 19, 2019
    Publication date: April 1, 2021
    Inventors: David Francis Alain LANÇOIS, Jérome Émile Georges GUILLEMONT, Pierre Jean-Marie Bernard RABOISSON, Peter RIGAUX, Antoine Benjamin MICHAUT, Sabrina Dany France QUATREVAUX, Sovy CHAO, Dirk André Emmy ROYMANS
  • Publication number: 20210040046
    Abstract: This application relates to quinazoline derivatives of formula (I), pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds of formula (I) in the treatment or prevention of a viral infection, of a virus-induced disease, of cancer or of an allergy.
    Type: Application
    Filed: February 28, 2019
    Publication date: February 11, 2021
    Applicant: Janssen Sciences Ireland Unlimi
    Inventors: David Craig MC GOWAN, Werner Constant Johan EMBRECHTS, Jérôme Émile Georges GUILLEMONT, Ludwig Paul COOYMANS, Tim Hugo Maria JONCKERS, Pierre Jean-Marie RABOISSON
  • Publication number: 20200361942
    Abstract: The invention concerns compounds having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection. Formula (Ia).
    Type: Application
    Filed: November 28, 2017
    Publication date: November 19, 2020
    Inventors: David Francis Alain LANÇOIS, Jérôme Émile Georges GUILLEMONT, Pierre Jean-Marie Bernard RABOISSON, Dirk André Emmy ROYMANS, Peter RIGAUX, Antoine Benjamin MICHAUT, Guillaume Jean Maurice MERCEY